Quest Diagnostics Inc (DGX) Holdings Reduced by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. lowered its position in Quest Diagnostics Inc (NYSE:DGX) by 90.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,689 shares of the medical research company’s stock after selling 140,052 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Quest Diagnostics were worth $1,585,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in DGX. Edgestream Partners L.P. lifted its stake in shares of Quest Diagnostics by 43.9% during the 3rd quarter. Edgestream Partners L.P. now owns 22,620 shares of the medical research company’s stock worth $2,441,000 after buying an additional 6,901 shares during the last quarter. Toronto Dominion Bank lifted its stake in shares of Quest Diagnostics by 1.6% during the 3rd quarter. Toronto Dominion Bank now owns 89,301 shares of the medical research company’s stock worth $9,634,000 after buying an additional 1,446 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Quest Diagnostics by 1.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 435,614 shares of the medical research company’s stock worth $47,007,000 after buying an additional 7,214 shares during the last quarter. Fort Washington Investment Advisors Inc. OH lifted its stake in shares of Quest Diagnostics by 162.2% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 5,955 shares of the medical research company’s stock worth $643,000 after buying an additional 3,684 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Quest Diagnostics by 70.2% during the 3rd quarter. SG Americas Securities LLC now owns 69,302 shares of the medical research company’s stock worth $7,478,000 after buying an additional 28,579 shares during the last quarter. Hedge funds and other institutional investors own 86.00% of the company’s stock.

Shares of Quest Diagnostics stock opened at $94.06 on Friday. Quest Diagnostics Inc has a twelve month low of $90.54 and a twelve month high of $116.49. The company has a quick ratio of 1.09, a current ratio of 1.15 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $12.68 billion, a price-to-earnings ratio of 17.42, a price-to-earnings-growth ratio of 1.68 and a beta of 0.90.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Tuesday, October 23rd. The medical research company reported $1.68 earnings per share for the quarter, hitting the consensus estimate of $1.68. Quest Diagnostics had a net margin of 11.30% and a return on equity of 15.71%. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.95 billion. During the same quarter in the previous year, the company earned $1.38 EPS. The business’s revenue was up 1.8% on a year-over-year basis. As a group, equities research analysts expect that Quest Diagnostics Inc will post 6.56 EPS for the current fiscal year.

A number of research firms have recently issued reports on DGX. JPMorgan Chase & Co. cut their target price on shares of Quest Diagnostics from $114.00 to $107.00 and set a “neutral” rating for the company in a research note on Wednesday, October 24th. Argus set a $120.00 target price on shares of Quest Diagnostics and gave the stock a “buy” rating in a research note on Friday, September 14th. William Blair restated an “outperform” rating on shares of Quest Diagnostics in a research note on Tuesday, October 23rd. Credit Suisse Group raised their target price on shares of Quest Diagnostics from $121.00 to $128.00 and gave the stock an “outperform” rating in a research note on Monday, September 24th. Finally, Canaccord Genuity cut their target price on shares of Quest Diagnostics from $118.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, October 24th. Eight analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $110.80.

TRADEMARK VIOLATION WARNING: “Quest Diagnostics Inc (DGX) Holdings Reduced by Candriam Luxembourg S.C.A.” was reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.wkrb13.com/2018/11/24/quest-diagnostics-inc-dgx-holdings-reduced-by-candriam-luxembourg-s-c-a.html.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Recommended Story: What Factors Can Affect Return on Equity?

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply